AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18087204 — intervention group
Group type: COMPARATOR
Intervention: Stopping antidepressants with additional preventive cognitive therapy (CT)
Number of subjects: 172
Study 18087204 — intervention group
Group type: COMPARATOR
Intervention: Non-AD-using patients treated with usual care
Number of subjects: 172
Study 16877900 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (40-120 mg/day)
Number of subjects: 2577
Study 16877900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2577
Study 16877900 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 2577
Study 12527617 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation (group V)
Number of subjects: 16
Study 12527617 — intervention group
Group type: COMPARATOR
Intervention: Manual ventilation (group M)
Number of subjects: 16
Study 10650299 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 0
Study 10650299 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9345375 — intervention group
Group type: EXPERIMENTAL
Intervention: Linomide (p.o.)
Number of subjects: 0
Study 9345375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1751434 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg mifepristone orally 36 h before operation
Number of subjects: 90
Study 1751434 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg gemeprost vaginal pessary 3‐4 h preoperatively
Number of subjects: 90
Study 1751434 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical oral placebo)
Number of subjects: 90
Study 6297363 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic human beta‐EP by constant rate IV infusion
Number of subjects: 18
Study 31249403 — intervention group
Group type: EXPERIMENTAL
Intervention: His bundle pacing (HBP)
Number of subjects: 0
Study 31249403 — intervention group
Group type: COMPARATOR
Intervention: RV apical pacing
Number of subjects: 0
Study 30792049 — intervention group
Group type: EXPERIMENTAL
Intervention: Antecolic reconstruction
Number of subjects: 30
Study 30792049 — intervention group
Group type: COMPARATOR
Intervention: Retrocolic reconstruction
Number of subjects: 30
Study 27687308 — intervention group
Group type: EXPERIMENTAL
Intervention: Early palliative care team referral
Number of subjects: 182
Study 27687308 — intervention group
Group type: COMPARATOR
Intervention: Standard oncology care with palliative care only as needed
Number of subjects: 182
Study 25907583 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed consent procedure (participant information sheet, informed consent form, and AUDIT questionnaire)
Number of subjects: 380
Study 25907583 — intervention group
Group type: COMPARATOR
Intervention: AUDIT questionnaire only (comparator group)
Number of subjects: 380
Study 23128033 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser treatment at 5.1 J/cm² (L(1))
Number of subjects: 12
Study 23128033 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser treatment at 2.0 J/cm² (L(2))
Number of subjects: 12
Study 23128033 — intervention group
Group type: COMPARATOR
Intervention: Control group (no laser treatment)
Number of subjects: 12
Study 21785107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2021
Study 19796823 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone acetonide (IVTA)
Number of subjects: 69
Study 19796823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 17102001 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost-timolol fixed combination dosed in the evening
Number of subjects: 0
Study 17102001 — intervention group
Group type: COMPARATOR
Intervention: Timolol alone dosed twice daily
Number of subjects: 0
Study 14724871 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalexin/penicillin combination
Number of subjects: 127
Study 14724871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 11769363 — intervention group
Group type: EXPERIMENTAL
Intervention: Family psychosocial intervention at diagnosis
Number of subjects: 36
Study 11769363 — intervention group
Group type: COMPARATOR
Intervention: Control group (hospital ward treatment)
Number of subjects: 36
Study 9397322 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training only (S)
Number of subjects: 45
Study 9397322 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training only (E)
Number of subjects: 45
Study 9397322 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined strength and endurance training (SE)
Number of subjects: 45
Study 9397322 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 45
Study 7555508 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose 100 mg three times daily
Number of subjects: 0
Study 7555508 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose 200 mg three times daily
Number of subjects: 0
Study 7555508 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose 300 mg three times daily
Number of subjects: 0
Study 7555508 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (all doses)
Number of subjects: 0
Study 7555508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2124925 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (F)
Number of subjects: 8
Study 2124925 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate diet (C)
Number of subjects: 8
Study 446319 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 1.6 g/d
Number of subjects: 36
Study 446319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 30221400 — intervention group
Group type: EXPERIMENTAL
Intervention: Probe-based confocal laser endomicroscopy (pCLE)
Number of subjects: 91
Study 30221400 — intervention group
Group type: COMPARATOR
Intervention: White light endoscopy (WLE)
Number of subjects: 91
Study 28241356 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone gel for 1 year
Number of subjects: 493
Study 28241356 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel for 1 year
Number of subjects: 493
Study 25878304 — intervention group
Group type: EXPERIMENTAL
Intervention: Open reduction and plate fixation
Number of subjects: 120
Study 25878304 — intervention group
Group type: COMPARATOR
Intervention: Intramedullary nailing
Number of subjects: 120
Study 24281841 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine colostrum (60 g/d)
Number of subjects: 40
Study 24281841 — intervention group
Group type: COMPARATOR
Intervention: Whey protein (38 g protein)
Number of subjects: 40
Study 24281841 — intervention group
Group type: COMPARATOR
Intervention: Both colostrum and whey protein
Number of subjects: 40
Study 22157845 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.125% (Group B)
Number of subjects: 105
Study 22157845 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.125% plus epinephrine 1:200 000 (Group BE)
Number of subjects: 105
Study 22157845 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine 1:200 000 (Group E)
Number of subjects: 105
Study 20231228 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (3 microg/kg)
Number of subjects: 30
Study 20231228 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (2 microg/kg) and succinylcholine (2 mg/kg)
Number of subjects: 30
Study 17664059 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant formula with 0.6 g/100 mL of galacto-oligosaccharides (GOS) and long-chain fructo-oligosaccharides (lcFOS) in a ratio of 9/1
Number of subjects: 215
Study 17664059 — intervention group
Group type: COMPARATOR
Intervention: Control infant formula
Number of subjects: 215
Study 17664059 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk
Number of subjects: 215
Study 17664059 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant formula with GOS/lcFOS
Number of subjects: 215
Study 16297753 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg/mL levobupivacaine (bolus 3.3 mL, lockout 20 minutes, n = 26)
Number of subjects: 49
Study 16297753 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/mL levobupivacaine (bolus 1 mL, lockout 20 minutes, n = 23)
Number of subjects: 49
Study 12475852 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics and colloids
Number of subjects: 37
Study 12475852 — intervention group
Group type: COMPARATOR
Intervention: Dual placebo
Number of subjects: 37
Study 9259653 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystography
Number of subjects: 211
Study 9259653 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history screening
Number of subjects: 211
Study 9259653 — intervention group
Group type: EXPERIMENTAL
Intervention: DMSA radioisotope scan
Number of subjects: 211
Study 9259653 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal ultrasound
Number of subjects: 211
Study 8332149 — intervention group
Group type: EXPERIMENTAL
Intervention: Holter monitoring
Number of subjects: 486
Study 8332149 — intervention group
Group type: COMPARATOR
Intervention: Electrophysiologic study
Number of subjects: 486
Study 8332149 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 486
Study 8332149 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous responders to antiarrhythmic drugs
Number of subjects: 486
Study 8332149 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall drug therapy success
Number of subjects: 486
Study 3553008 — intervention group
Group type: EXPERIMENTAL
Intervention: 7‐S‐immunoglobulins
Number of subjects: 44
Study 3553008 — intervention group
Group type: COMPARATOR
Intervention: Control group (not treated with immunoglobulins)
Number of subjects: 44
Study 29607761 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip arthroscopic procedures
Number of subjects: 240
Study 29607761 — intervention group
Group type: COMPARATOR
Intervention: Sham surgery
Number of subjects: 240
Study 27156803 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical needling combined with non-cultured autologous skin cell suspension (NCASCS)
Number of subjects: 20
Study 25444575 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (high intensity progressive resistance training)
Number of subjects: 100
Study 25444575 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 100
Study 25444575 — intervention group
Group type: COMPARATOR
Intervention: Cognitive training
Number of subjects: 100
Study 22956551 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg oral prednisolone daily for 4 weeks
Number of subjects: 70
Study 22956551 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 20633522 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 63
Study 20633522 — intervention group
Group type: COMPARATOR
Intervention: Sham Acupuncture
Number of subjects: 63
Study 18583886 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild cognitive impairment (MCI) patients
Number of subjects: 22
Study 18583886 — intervention group
Group type: COMPARATOR
Intervention: Elderly normal controls
Number of subjects: 22
Study 16211697 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (CE) and medroxyprogesterone acetate (MPA) at a dose of 0.625/2.5 mg daily for 24 weeks
Number of subjects: 1028
Study 16211697 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (CE) and medroxyprogesterone acetate (MPA) at a dose of 0.45/1.5 mg daily for 24 weeks
Number of subjects: 1028
Study 16211697 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (CE) and medroxyprogesterone acetate (MPA) at a dose of 0.3/1.5 mg daily for 24 weeks
Number of subjects: 1028
Study 16211697 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal responsiveness evaluated by the vaginal maturation index (VMI) at baseline and at week 24
Number of subjects: 1028
Study 11908554 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam 7.5 mg
Number of subjects: 894
Study 11908554 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam 15 mg
Number of subjects: 894
Study 11908554 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam 22.5 mg
Number of subjects: 894
Study 11908554 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 150 mg
Number of subjects: 894
Study 11908554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 894
Study 11908554 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of meloxicam and diclofenac
Number of subjects: 894
Study 10579069 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmyocardial laser revascularization (TMR)
Number of subjects: 0
Study 8776076 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized exercise conditioning program for 15 weeks
Number of subjects: 39
Study 8776076 — intervention group
Group type: COMPARATOR
Intervention: Oral drug therapy
Number of subjects: 39
Study 1760998 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat diet (25% of energy) with low P/S ratio (less than 0.4)
Number of subjects: 4
Study 1760998 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat diet (35% of energy) with high P/S ratio (greater than 1.0)
Number of subjects: 4
Study 1760998 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat diet (25% of energy) with high P/S ratio (greater than 1.0)
Number of subjects: 4
Study 1760998 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat diet (35% of energy) with low P/S ratio (less than 0.4)
Number of subjects: 4
Study 1760998 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (6 g daily for four weeks)
Number of subjects: 4
Study 6122098 — intervention group
Group type: EXPERIMENTAL
Intervention: GL enzyme
Number of subjects: 71
Study 6122098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 31640992 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management programme
Number of subjects: 0
Study 31640992 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management programme plus a verum thumb splint
Number of subjects: 0
Study 31640992 — intervention group
Group type: COMPARATOR
Intervention: Self-management programme plus a placebo thumb splint
Number of subjects: 0
Study 30089430 — intervention group
Group type: EXPERIMENTAL
Intervention: 10,000 therapeutic units (TU) of Dermatophagoides pteronyssinus allergoid preparation
Number of subjects: 146
Study 30089430 — intervention group
Group type: EXPERIMENTAL
Intervention: 18,000 therapeutic units (TU) of Dermatophagoides pteronyssinus allergoid preparation
Number of subjects: 146
Study 30089430 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 27100435 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid infancy weight gain (weight-for-age Z score gain >0.67 between birth and 1.5 years)
Number of subjects: 581
Study 27100435 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid infancy weight gain
Number of subjects: 581
Study 24663007 — intervention group
Group type: EXPERIMENTAL
Intervention: Twin Block (TB) appliance therapy
Number of subjects: 39
Study 24663007 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbst appliance therapy
Number of subjects: 39
Study 24663007 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study 24663007 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TB and Herbst appliances
Number of subjects: 39
Study 22324448 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic formulation containing Lactobacillus paracasei B21060, arabinogalactan and xilooligosaccharides
Number of subjects: 107
Study 22324448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 22324448 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic formulation
Number of subjects: 107
Study 19224955 — intervention group
Group type: EXPERIMENTAL
Intervention: Q measurement system implemented in hospitals
Number of subjects: 30
Study 19224955 — intervention group
Group type: EXPERIMENTAL
Intervention: Q measurement system
Number of subjects: 30
Study 19224955 — intervention group
Group type: EXPERIMENTAL
Intervention: Operational costs of implementing Q
Number of subjects: 30
Study 17608790 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 35048
Study 17608790 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 35048
Study 17608790 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 35048
Study 17608790 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 35048
Study 17608790 — intervention group
Group type: EXPERIMENTAL
Intervention: AGT-6 genotype 'G/G' in men
Number of subjects: 35048
Study 17608790 — intervention group
Group type: EXPERIMENTAL
Intervention: AGT-6 genotype 'G/G' in women
Number of subjects: 35048
Study 17608790 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE-I/D genotype
Number of subjects: 35048
Study 15140460 — intervention group
Group type: EXPERIMENTAL
Intervention: decision analytic decision aid (DA)
Number of subjects: 15
Study 15140460 — intervention group
Group type: EXPERIMENTAL
Intervention: computerised decision aid
Number of subjects: 15
Study 11148745 — intervention group
Group type: EXPERIMENTAL
Intervention: Holmium laser prostatectomy
Number of subjects: 0
Study 11148745 — intervention group
Group type: EXPERIMENTAL
Intervention: Interstitial laser prostatectomy
Number of subjects: 0
Study 11148745 — intervention group
Group type: COMPARATOR
Intervention: Neodymium:yttrium‐aluminum‐garnet laser
Number of subjects: 0
Study 9672822 — intervention group
Group type: EXPERIMENTAL
Intervention: Coached malingerers
Number of subjects: 92
Study 9672822 — intervention group
Group type: EXPERIMENTAL
Intervention: Naive malingerers
Number of subjects: 92
Study 9672822 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 92
Study 8076564 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:10,000 epinephrine in water (Group I)
Number of subjects: 52
Study 8076564 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (Group II)
Number of subjects: 52
Study 2644753 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia (TEA) with bupivacaine 50 mg via an epidural catheter, maintained by continuous infusion for 24 hours postoperatively.
Number of subjects: 16
Study 2644753 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia only (control group).
Number of subjects: 16
Study 186225 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ingestion of orthophosphate (Pi)
Number of subjects: 10
Study 186225 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal arterial infusion of orthophosphate (Pi) in dogs
Number of subjects: 10
Study 186225 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous intravenous infusion of PPi in dogs
Number of subjects: 10
Study 186225 — intervention group
Group type: COMPARATOR
Intervention: Infusion of PPi in dogs
Number of subjects: 10
Study 29093253 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive intervention for one year
Number of subjects: 0
Study 29093253 — intervention group
Group type: COMPARATOR
Intervention: Routine health education (Control)
Number of subjects: 0
Study 25119120 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutures
Number of subjects: 126
Study 25119120 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable mesh
Number of subjects: 126
Study 25119120 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonabsorbable mesh
Number of subjects: 126
Study 24010771 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-brain irradiation (WBI) with concomitant chloroquine (CLQ) 150 mg for 4 weeks
Number of subjects: 73
Study 24010771 — intervention group
Group type: COMPARATOR
Intervention: Whole-brain irradiation (WBI) with placebo for 4 weeks
Number of subjects: 73
Study 21696614 — intervention group
Group type: EXPERIMENTAL
Intervention: RTA victims
Number of subjects: 150
Study 21696614 — intervention group
Group type: COMPARATOR
Intervention: Control group 1
Number of subjects: 150
Study 21696614 — intervention group
Group type: COMPARATOR
Intervention: Control group 2
Number of subjects: 150
Study 18096368 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich fluid (800 mL evening before surgery and 400 mL 2 hours preoperatively)
Number of subjects: 70
Study 18096368 — intervention group
Group type: COMPARATOR
Intervention: Control (overnight fasting)
Number of subjects: 70
Study 18096368 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich fluid
Number of subjects: 70
Study 16562706 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily health education at DOTS centres
Number of subjects: 234
Study 16562706 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly observed treatment
Number of subjects: 234
Study 16562706 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 234
Study 16562706 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of TB
Number of subjects: 234
Study 16562706 — intervention group
Group type: EXPERIMENTAL
Intervention: Availability of daily health education
Number of subjects: 234
Study 16562706 — intervention group
Group type: COMPARATOR
Intervention: Non-adherent patients
Number of subjects: 234
Study 12974867 — intervention group
Group type: EXPERIMENTAL
Intervention: Ca(OH)2 and distilled water mixture
Number of subjects: 45
Study 12974867 — intervention group
Group type: EXPERIMENTAL
Intervention: TempCanal
Number of subjects: 45
Study 12974867 — intervention group
Group type: EXPERIMENTAL
Intervention: Calasept
Number of subjects: 45
Study 12974867 — intervention group
Group type: EXPERIMENTAL
Intervention: Ca(OH)2 plus point
Number of subjects: 45
Study 12974867 — intervention group
Group type: COMPARATOR
Intervention: Control group (nothing applied)
Number of subjects: 45
Study 10732825 — intervention group
Group type: EXPERIMENTAL
Intervention: Perilla seed oil-rich supplementation for 4 weeks
Number of subjects: 14
Study 10732825 — intervention group
Group type: COMPARATOR
Intervention: Corn oil-rich supplementation for 4 weeks
Number of subjects: 14
Study 9013264 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine infusion (3 micrograms/kg/min)
Number of subjects: 18
Study 9013264 — intervention group
Group type: COMPARATOR
Intervention: Baseline IL6 levels
Number of subjects: 18
Study 9013264 — intervention group
Group type: EXPERIMENTAL
Intervention: IL6 levels after 24 hours
Number of subjects: 18
Study 9013264 — intervention group
Group type: EXPERIMENTAL
Intervention: IL6 levels in sicker patients
Number of subjects: 18
Study 1312340 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar gum (15 g)
Number of subjects: 5